NPM1 ‐mutated AML : One entity, multiple layers of heterogeneity
British Journal of Haematology · 11.11.2026
DOI: 10.1111/bjh.70954 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 11.11.2026. Verfasst von Manja Meggendorfer und 1 weiteren Autor:innen. Beteiligte Einrichtung: MLL Munich Leukemia Laboratory, Munich, Germany. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Nucleophosmin 1 ( NPM1 ) mutations are found in around one third of all acute myeloid leukaemias (AMLs). However, little is known about the clinical role of the rare, non‐A NPM1 variants. Sangiorgio et al. showed that rare variants shared a similar molecular background and overall survival to the common type A, with FMS‐like tyrosine kinase 3 ( FLT3 ) status as the main determinant of outcome. Commentary on: Sangiorgio et al. Rare variants of NPM1 mutations share a similar molecular background to the common NPM1 type A variant and are associated with similar survival in adults with acute myeloid leukaemia. Br J Haematol 2026 (Online ahead of print). doi: 10.1182/blood‐2024‐202884 .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- MLL Munich Leukemia Laboratory, Munich, Germany.
ORCID-Profile: Manja Meggendorfer, Wolfgang Kern
Zitieren
APA
Meggendorfer, M., & Kern, W. (2026). NPM1 ‐mutated AML : One entity, multiple layers of heterogeneity. British Journal of Haematology. https://doi.org/10.1111/bjh.70954
Vancouver
Meggendorfer M, Kern W. NPM1 ‐mutated AML : One entity, multiple layers of heterogeneity. British Journal of Haematology. 2026. doi:10.1111/bjh.70954
BibTeX
@article{Meggendorfer2026,
author = {Meggendorfer, Manja and Kern, Wolfgang},
title = {NPM1 ‐mutated AML : One entity, multiple layers of heterogeneity},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70954}
}
EUVIMED